Transparent communication : The clinic should provide clear information about the therapy, including potential risks and expected outcomes
Diabetes Care 32(7):13271334 Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, Varbo A, Wilding JPH, Wallenstein SOR, le Roux CW (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program
We work with top MDs, PAs, NPs, and more to reach our shared goal of giving patients the best experience, with optimal results
Furthermore, patients are encouraged to verify coverage with their insurance providers, as tirzepatide coverage can vary significantly